Role of apoE/Aβ interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy

Journal of Molecular Neuroscience

Volumn 17, Issue 2, 2001, Pages 147-155

  Holtzman, D M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid; Apolipoprotein E

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CHAPERONE;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DEGENERATIVE DISEASE; GENE MUTATION; HUMAN; MOUSE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PROTEIN PROTEIN INTERACTION; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS; ANIMAL; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PROTEIN SECONDARY STRUCTURE; REVIEW;

ANIMALIA; MURINAE; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMAL; APOLIPOPROTEINS E; CEREBRAL AMYLOID ANGIOPATHY; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMAN; MICE; MICE, TRANSGENIC; MOLECULAR CHAPERONES; PROTEIN STRUCTURE, SECONDARY; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0034746840     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:17:2:147     Document Type: Article

References (85)

1. Interaction of nascent apoE2, apoE3, and apoE4 isoforms expressed in mammalian cells with amyloid peptide β1-40 Relevance to Alzheimer's disease
2. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele
3. V717F transgenic mouse model of Alzheimer's disease
4. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
5. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures
6. Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: Analysis of betaAPP processing
7. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid
8. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system
9. Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease
10. Expression of human apolipoprotein E3 or E4 in the brains of apoe/mice: Isoform-specific effects on neurodegeneration
11. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E
12. Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system and inAlzheimer's disease
13. Protective effect of apolipoprotein E type 2 allele decreases risk of late onset Alzhimer disease
14. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
15. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer's disease
16. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-) and human apoE transgenic mice
17. Differences inAβ40/42 ratio associated with CSF lipoproteins as a function of apoE genotype
18. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
19. Fate of cerebrospinal fluid-borne amyloid [beta]-peptide: Rapid clearance into blood and appreciable accumulation by cerebral arteries
20. The interaction between apolipoprotein E and Alzheimer's amyloid β-peptide is dependent on β-peptide conformation
21. Apolipoprotein E Σ4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy
22. Apolipoprotein E Σ4 and cerebral hemorrhage associated with amyloid angiopathy
23. Association of apolipoprotein E Σ2 and vasculopathy in cerebral amyloid angiopathy
24. ApoE genotype and Down's syndrome
25. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease
26. In vivo expression of apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimers disease
27. ApoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease
28. LRP mediates apolipoprotein E-dependent neurite outgrowth in a CNS-derived neuronal cell line
29. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
30. Quantitative analysis of senile plaques in Alzheimer disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21
31. Molecular characterization of a novel human hybrid-type receptor that binds the α2-macroglobulin receptor-associated protein
32. Cerebrovascular amyloidosis with cerebral hemorrhage
33. Amyloid β40/42 clearance across the blood-brain barrier following intraventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice
34. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain
35. Reduction in amyloid A formation in apolipoprotein-E-deficient mice
36. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma
37. Biochemical characterization of Alzheimer's soluble beta protein in human cerebrospinal fluid-association with high density lipoprotein
38. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins
39. Isoform-specific binding of apolipoprotein E to β-amyloid
40. Nascent astroctye particles differ from lipoproteins in CSF
41. Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid
42. APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome
43. Structural neurology: Are seeds at the root of neuronal degeneration?
44. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation
45. Amyloid-associated proteins alpha-1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments
46. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
47. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome
48. The apolipoprotein Σ4 allele in patients withAlzheimer's disease
49. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's diesase kuru plaque amyloid in Creutzfeldt-Jacob disease
50. Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide inAlzheimer's disease brain
51. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro
52. Combined amyloid vascular changes and argyrophilic plaques in the central nervous system
53. High frequency of apolipoprotein E Σ2 allele in hemorrhage due to cerebral amyloid angiopathy
54. Detection of apolipoprotein E/dimeric soluble amyloid β complexes in Alzheimer's disease brain supernatants
55. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
56. Lipoproteins and their receptors in the central nervous system
57. Apolipoprotein E and the apolipoprotein E-deficient mouse
58. Apolipoprotein E in animal models of CNS injury and Alzheimer's disease
59. Apolipoprotein E-Σ4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease
60. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease
61. Alzheimer's disease: Apolipoprotein E and cognitive performance
62. Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes
63. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
64. Amyloid A4 protein and its precursors in Down's syndrome and Alzheimer's disease
65. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease
66. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils
67. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein genotype in late-onset Alzheimer disease
68. Alzheimer's disease: Genotypes, phenotype, and treatments
69. Clearance of Alzheimer's amyloid-β1740 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier
70. Alzheimer's β-amyloid peptide is conformationally modified by apolipoprotein E in vitro
71. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro
72. Apolipoprotein E and Alzheimer's disease
73. Apolipoprotein E: High avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
74. Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform specific-effects and implications for late-onset Alzheimer disease
75. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis
76. Localization of mRNA for low density lipoprotein receptor and a cholesterol synthetic enzyme in rabbit nervous system by in situ hybridization
77. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides
78. Cerebral amyloid angiopathy: A critical review
79. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome
80. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid
81. Is Alzheimer's disease an apolipoprotein E amyloidosis?
82. Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E
83. Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member
84. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner
85. Characterization of the binding of amyloid-β peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma